Most previous large studies of carotid artery stenting (CAS) in maintenance hemodialysis patients are old-era, do not describe the types of stents and method of protection, and their effectiveness is unknown. CAS has progressed remarkably, and tailor-made CAS is now possible in hemodialysis patients according to the lesion. We aimed to analyze the outcomes of CAS in maintenance hemodialysis patients treated in our institution.We retrospectively investigated the data of patients who underwent elective CAS in our institution between January 2012 and April 2023. Firstly, we verified the outcomes of CAS in maintenance hemodialysis patients. Secondly, the outcomes of CAS in maintenance hemodialysis patients were compared with CAS in nondialysis patients during the same period.During the study period, 212 patients with carotid stenosis underwent CAS. Among these, 18 patients undergoing maintenance hemodialysis were identified for analysis. All 18 patients underwent lesion-specific tailor-made CAS. All 18 patients were technically successfully stented with good vasodilation and improvement in stenosis. No symptomatic cerebral infarction occurred within 30 days after CAS. There was no difference between dialysis and nondialysis patients in the risk of symptomatic complications and death occurring within 30 days after surgery. There was a higher risk of hemorrhagic complications not associated with prognosis in the dialysis group (23.1% vs 1.0%, P = 0.0047). No in-stent restenosis (>50% stenosis) and ipsilateral cerebral infarction at 1 year occurred during follow-up.CAS in hemodialysis patients may be safe and effective.

Download full-text PDF

Source
http://dx.doi.org/10.2176/jns-nmc.2024-0193DOI Listing

Publication Analysis

Top Keywords

hemodialysis patients
28
maintenance hemodialysis
24
cas maintenance
16
patients
14
carotid artery
12
outcomes cas
12
cas
11
artery stenting
8
hemodialysis
8
tailor-made cas
8

Similar Publications

Objective: Patients with chronic kidney disease (CKD) have an increased risk of adverse cardio-cerebrovascular events. The purpose of this study is to evaluate the prognostic predictors over 5 years in patients with CKD including haemodialysis.

Methods: In this multicenter, prospective cohort study performed with the Gunma-CKD SPECT Study protocol, 311 patients with CKD [estimated glomerular filtration rate (eGFR) < 60 min/ml/1.

View Article and Find Full Text PDF

Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation.

Endocr Metab Immune Disord Drug Targets

January 2025

Sheba Medical Center, Institute of Endocrinology, Tel-Hashomer, Israel.

SGLT2 inhibitors are a family of drugs that were developed to treat diabetes mellitus. In randomized controlled trials, SGLT2 inhibitors seem to prevent kidney deterioration in patients with nephropathies, both diabetic and non-diabetic. However, in contrast to biochemical/physiological results (proteinuria and serum creatinine levels) that improve in all studies, the clinical results (all-cause mortality, cardiovascular death, need for dialysis, or renal transplant) do not consistently improve.

View Article and Find Full Text PDF

Background: Following COVID-19, dietary habits have been altered frequently along with other societal lifestyle modifications. However, changes in the dietary habits of maintenance hemodialysis patients (MHPs) before and during COVID-19 have not been investigated.

Methods: A total of 132 MHPs were assessed for changes in their dietary habits before and during the pandemic and their association with COVID-19 prevention.

View Article and Find Full Text PDF

Objective: Cognitive impairment is a recurrent complication in people with chronic kidney disease (CKD), which includes those undergoing hemodialysis (HD). Researchers aimed to analyze vitamin D levels, beta-amyloid 42, indoxyl sulfate, and serum parathyroid hormone (PTH) in patients with cognitive impairment who underwent HD.

Design: This comparative, cross-sectional study was conducted at the HD unit of Dr.

View Article and Find Full Text PDF

Background: Hemophagocytic lymphohistiocytosis (HLH) is a non-neoplastic proliferation and macrophage activation that induces cytokine-mediated bone marrow suppression and features of intense phagocytosis in the bone marrow and liver, leading to multi-organ dysfunction and ultimate failure. The diagnosis of HLH in an intensive care setting is challenging, and it is associated with high morbidity and mortality. HLH-94 is the standard protocol for treatment, consisting of dexamethasone and chemotherapy like etoposide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!